Fennec Pharmaceuticals (FENC) Expected to Announce Quarterly Earnings on Monday

Fennec Pharmaceuticals (NASDAQ:FENC) is projected to issue its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.56 per share and revenue of $16.42 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Fennec Pharmaceuticals Stock Up 1.0 %

Shares of NASDAQ FENC opened at $6.88 on Friday. Fennec Pharmaceuticals has a fifty-two week low of $3.96 and a fifty-two week high of $11.49. The business has a 50 day moving average price of $6.39 and a two-hundred day moving average price of $5.61. The firm has a market cap of $189.63 million, a PE ratio of -68.79 and a beta of 0.34.

Analyst Ratings Changes

A number of brokerages have weighed in on FENC. Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Finally, Wedbush restated an “outperform” rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research note on Friday, December 20th.

Insider Buying and Selling at Fennec Pharmaceuticals

In other news, Director Rosty Raykov sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $6.08, for a total value of $60,800.00. Following the sale, the director now owns 83,863 shares of the company’s stock, valued at approximately $509,887.04. The trade was a 10.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 31,186 shares of company stock valued at $203,389 in the last quarter. Corporate insiders own 10.98% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.